deltatrials
Completed PHASE1 NCT00153543

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Sponsor: Alaska Native Tribal Health Consortium

Conditions Pneumococcal Infections
Interventions PCV7 + PPV23, 2 months PCV7 + PPV23, 6 months
Updated 6 times since 2017 Last updated: Sep 26, 2024 Started: May 31, 2002 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

This PHASE1 trial investigates Pneumococcal Infections and is currently completed. Alaska Native Tribal Health Consortium leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Oct 2024 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alaska Native Tribal Health Consortium
  • Centers for Disease Control and Prevention
  • Southcentral Foundation
Data source: Centers for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Anchorage, United States